Common and specific liability to addiction: Approaches to association studies of opioid addiction

Drug and Alcohol Dependence

Volumn 123, Issue SUPPL.1, 2012, Pages

  Nielsen, David A ^a,b   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

DRUG ABUSE; EPIGENETICS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HEROIN DEPENDENCE; HUMAN; NOTE; OPIATE ADDICTION; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; OPIOID-RELATED DISORDERS; PHENOTYPE;

EID: 84862899933     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.03.026     Document Type: Note

References (113)

1. Adams J., Crosbie J., Wigg K., Ickowicz A., Pathare T., Roberts W., Malone M., Schachar R., Tannock R., Kennedy J.L., Barr C.L. Glutamate receptor, ionotropic, N-methyl d-aspartate 2A (GRIN2A) gene as a positional candidate for attention-deficit/hyperactivity disorder in the 16p13 region. Mol. Psychiatry 2004, 9:494-499.
2. Alikhani-Koopaei R., Fouladkou F., Frey F.J., Frey B.M. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J. Clin. Invest. 2004, 114:1146-1157.
3. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
4. Antequera F., Bird A. Number of CpG islands and genes in human and mouse. Proc. Natl. Acad. Sci. USA 1993, 90:11995-11999.
5. Anton R.F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 2008, 65:135-144.
6. Arias A., Feinn R., Kranzler H.R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006, 83:262-268.
7. Barnby G., Abbott A., Sykes N., Morris A., Weeks D.E., Mott R., Lamb J., Bailey A.J., Monaco A.P., International Molecular Genetics Study of Autism Consortium Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT. Am. J. Hum. Genet. 2005, 76:950-966.
8. Bart G., Heilig M., LaForge K.S., Pollak L., Leal S.M., Ott J., Kreek M.J. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry 2004, 9:547-549.
9. Bart G., Kreek M.J., Ott J., LaForge K.S., Proudnikov D., Pollak L., Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005, 30:417-422.
10. Belfer I., Hipp H., McKnight C., Evans C., Buzas B., Bollettino A., Albaugh B., Virkkunen M., Yuan Q., Max M.B., Goldman D., Enoch M.A. Association of galanin haplotypes with alcoholism and anxiety in two ethnically distinct populations. Mol. Psychiatry 2006, 11:301-311.
11. Benyamin B., McRae A.F., Zhu G., Gordon S., Henders A.K., Palotie A., Peltonen L., Martin N.G., Montgomery G.W., Whitfield J.B., Visscher P.M. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am. J. Hum. Genet. 2009, 84:60-65.
12. Bergen A.W., Kokoszka J., Peterson R., Long J.C., Virkkunen M., Linnoila M., Goldman G. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 1997, 2:490-494.
13. Bestor T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 2000, 9:2395-2402.
14. Bierut L.J. Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. Trends Pharmacol. Sci. 2010, 31:46-51.
15. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9608-9613.
16. Brigman J.L., Feyder M., Saksida L.M., Bussey T.J., Mishina M., Holmes A. Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit. Learn. Mem. 2008, 15:50-54.
17. Carninci P. Molecular biology: the long and short of RNAs. Nature 2009, 457:974-975.
18. Cheng C.Y., Hong C.J., Yu Y.W., Chen T.J., Wu H.C., Tsai S.J. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res. Mol. Brain Res. 2005, 140:86-90.
19. Core L.J., Waterfall J.J., Lis J.T. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 2008, 322:1845-1848.
20. Cui Y., Li G., Shaoyu Li S., Wu R. Designs for linkage analysis and association studies of complex diseases. Methods Mol. Biol. 2010, 620:219-242.
21. Deb I., Chakraborty J., Gangopadhyay P.K., Choudhury S.R., Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J. Neurochem. 2010, 112:486-496.
22. Devlin B., Roeder K., Wasserman L. Genomic control, a new approach to genetic-based association studies. Theor. Popul. Biol. 2001, 60:155-166.
23. Douet V., Heller M.B., Le Saux O. DNA methylation and Sp1 binding determine the tissue-specific transcriptional activity of the mouse Abcc6 promoter. Biochem. Biophys. Res. Commun. 2007, 354:66-71.
24. Eberharter A., Becker P.B. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 2002, 3:224-229.
25. Enoch M.A., Shen P.H., Xu K., Hodgkinson C., Goldman D. Using ancestry-informative markers to define populations and detect population stratification. J. Psychopharmacol. 2006, 20:19-26.
26. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis Disorders-Patient Edition, SCID-I/P, Version 2.0, 8/98 revision 1998, New York State Psychiatric Institute, Biometrics Research Department.
27. Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 1987, 196:261-282.
28. Gerra G., Garofano L., Santoro G., Bosari S., Pellegrini C., Zaimovic A., Moi A., Brambilla F., Mameli A., Pizzamiglio M., Donnini C. Association between low-activity serotonin transporter genotype and heroin dependence: behavioral and personality correlates. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 126B:37-42.
29. Gerra G., Leonardi C., Cortese E., D'Amore A., Lucchini A., Strepparola G., Serio G., Farina G., Magnelli F., Zaimovic A., Mancini A., Turci M., Manfredini M., Donnini C. Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144:771-775.
30. Ghildiyal M., Zamore P.D. Small silencing RNAs: an expanding universe. Nat. Rev. Genet. 2009, 10:94-108.
31. Glatt S.J., Su J.A., Zhu S.C., Zhang R., Zhang B., Li J., Lyons M.J., Faraone S.V., Tsuang M.T. Genome-wide linkage analysis of heroin dependence in Han Chinese: results from wave one of a multi-stage study. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2006, 141B:648-652.
32. Glatt S.J., Bousman C., Wang R.S., Murthy K.K., Rana B.K., Lasky-Su J.A., Zhu S.C., Zhang R., Li J., Zhang B., Li J., Lyons M.J., Faraone S.V., Tsuang M.T. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend. 2007, 90:159-165.
33. Gong J., Strong J.A., Zhang S., Yue X., Dehaven R.N., Daubert J.D., Cassel J.A., Yu G., Mansson E., Yu L. Endomorphins fully activate a cloned human mu opioid receptor. FEBS Lett. 1998, 439:152-156.
34. Hardy J., Singleton A. Genomewide association studies and human disease. N. Engl. J. Med. 2009, 360:1759-1768.
35. Hattori E., Liu C., Zhu H., Gershon E.S. Genetic tests of biologic systems in affective disorders. Mol. Psychiatry 2005, 10:719-740.
36. Hodgkinson C.A., Yuan Q., Xu K., Shen P.H., Heinz E., Lobos E.A., Binder E.B., Cubells J., Ehlers C.L., Gelernter J., Mann J., Riley B., Roy A., Tabakoff B., Todd R.D., Zhou Z., Goldman D. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol. 2008, 43:505-515.
37. Hou Q.F., Li S.B. Potential association of DRD2 and DAT1 genetic variation with heroin dependence. Neurosci. Lett. 2009, 464:127-130.
38. Huang W., Ma J.Z., Payne T.J., Beuten J., Dupont R.T., Li M.D. Significant association of DRD1 with nicotine dependence. Hum. Genet. 2008, 123:133-140.
39. Itokawa M., Yamada K., Yoshitsugu K., Toyota T., Suga T., Ohba H., Watanabe A., Hattori E., Shimizu H., Kumakura T., Ebihara M., Meerabux J.M., Toru M., Yoshikawa T. A microsatellite repeat in the promoter of the N-methyl-d-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 2003, 13:271-278.
40. Kapranov P., Cheng J., Dike S., Nix D.A., Duttagupta R., Willingham A.T., Stadler P.F., Hertel J., Hackermüller J., Hofacker I.L., Bell I., Cheung E., Drenkow J., Dumais E., Patel S., Helt G., Ganesh M., Ghosh S., Piccolboni A., Sementchenko V., Tammana H., Gingeras T.R. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007, 316:1484-1488.
41. Kapur S., Sharad S., Singh R.A., Gupta A.K. A118G polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J. Integr. Neurosci. 2007, 6:511-522.
42. Kellogg S.H., McHugh P.F., Bell K., Schluger J.H., Schluger R.P., LaForge K.S., Ho A., Kreek M.J. The Kreek-McHugh-Schluger-Kellogg scale: a new, rapid method for quantifying substance abuse and its possible applications. Drug Alcohol Depend. 2003, 69:137-150.
43. Kendler K.S., Jacobson K.C., Prescott C.A., Neale M.C. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am. J. Psychiatry 2003, 160:687-695.
44. Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
45. Knafo A., Israel S., Darvasi A., Bachner-Melman R., Uzefovsky F., Cohen L., Feldman E., Lerer E., Laiba E., Raz Y., Nemanov L., Gritsenko I., Dina C., Agam G., Dean B., Bornstein G., Ebstein R.P. Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA. Genes Brain Behav. 2008, 7:266-275.
46. Kong A., Steinthorsdottir V., Masson G., Thorleifsson G., Sulem P., Besenbacher S., Jonasdottir A., Sigurdsson A., Kristinsson K.T., Jonasdottir A., Frigge M.L., Gylfason A., Olason P.I., Gudjonsson S.A., Sverrisson S., Stacey S.N., Sigurgeirsson B., Benediktsdottir K.R., Sigurdsson H., Jonsson T., Benediktsson R., Olafsson J.H., Johannsson O.T., Hreidarsson A.B., Sigurdsson G., DIAGRAM Consortium, Ferguson-Smith A.C., Gudbjartsson D.F., Thorsteinsdottir U., Stefansson K. Parental origin of sequence variants associated with complex diseases. Nature 2009, 462:868-874.
47. Kreek M.J., Bart G., Lilly C., LaForge K.S., Nielsen D.A. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol. Rev. 2005, 57:1-26.
48. Kreek M.J., LaForge K.S. Stress responsivity, addiction, and a functional variant of the human mu-opioid receptor gene. Mol. Interv. 2007, 7:74-78.
49. Kreek M.J., Nielsen D.A., Butelman E.R., LaForge K.S. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat. Neurosci. 2005, 8:1450-1457.
50. Kreek M.J., Zhou Y., Butelman E.R., Levran O. Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr. Opin. Pharmacol. 2009, 9:74-80.
51. Kroslak T., LaForge K.S., Gianotti R.J., Ho A., Nielsen D.A., Kreek M.J. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J. Neurochem. 2007, 103:77-87.
52. Kumar A., Choi K.H., Renthal W., Tsankova N.M., Theobald D.E., Truong H.T., Russo S.J., Laplant Q., Sasaki T.S., Whistler K.N., Neve R.L., Self D.W., Nestler E.J. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 2005, 48:303-314.
53. Lachman H.M., Fann C.S., Bartzis M., Evgrafov O.V., Rosenthal R.N., Nunes E.V., Miner C., Santana M., Gaffney J., Riddick A., Hsu C.L., Knowles J.A. Genomewide suggestive linkage of opioid dependence to chromosome 4q. Hum. Mol. Genet. 2007, 16:1327-1334.
54. Lappalainen J., Krupitsky E., Kranzler H.R., Luo X., Remizov M., Pchelina S., Taraskina A., Zvartau E., Räsanen P., Makikyro T., Somberg L.K., Krystal J.H., Stein M.B., Gelernter J. Mutation screen of the GAD2 gene and association study of alcoholism in three populations. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144:183-192.
55. Levran O., Londono D., O'Hara K., Nielsen D.A., Peles E., Rotrosen J., Casadonte P., Linzy S., Randesi M., Ott J., Kreek M.J. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 2008, 7:720-729.
56. Levran O., Londono D., O'Hara K., Randesi M., Rotrosen J., Casadonte P., Linzy S., Ott J., Adelson M., Kreek M.J. Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav. 2009, 8:531-540.
57. Li M.D., Burmeister M. New insights into the genetics of addiction. Nat. Rev. Genet. 2009, 10:225-231.
58. Loh E.W., Lane H.Y., Chen C.H., Chang P.S., Ku L.W., Wang K.H., Cheng A.T. Glutamate decarboxylase genes and alcoholism in Han Taiwanese men. Alcohol. Clin. Exp. Res. 2006, 30:1817-1823.
59. Loh E.W., Tang N.L., Lee D.T., Liu S.I., Stadlin A. Association analysis of GABA receptor subunit genes on 5q33 with heroin dependence in a Chinese male population. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144:439-443.
60. Luo X., Kranzler H.R., Zuo L., Wang S., Blumberg H.P., Gelernter J. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. Hum. Mol. Genet. 2005, 14:2421-2434.
61. Luo X., Kranzler H.R., Zuo L., Wang S., Schork N.J., Gelernter J. Diplotype trend regression analysis of the ADH gene cluster and the ALDH2 gene: multiple significant associations with alcohol dependence. Am. J. Hum. Genet. 2006, 78:973-987.
62. Luo X., Kranzler H.R., Zuo L., Wang S., Schork N.J., Gelernter J. Multiple ADH genes modulate risk for drug dependence in both African- and European-Americans. Hum. Mol. Genet. 2007, 16:380-390.
63. Luo X., Kranzler H.R., Zuo L., Zhang H., Wang S., Gelernter J. ADH7 variation modulates extraversion and conscientiousness in substance-dependent subjects. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147B:179-186.
64. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A., Cho J.H., Guttmacher A.E., Kong A., Kruglyak L., Mardis E., Rotimi C.N., Slatkin M., Valle D., Whittemore A.S., Boehne M., Clark A.G., Eichler E.E., Gibson G., Haines J.L., Mackay T.F., McCarroll S.A., Visscher P.M. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
65. Maze I., Covington H.E., Dietz D.M., LaPlant Q., Renthal W., Russo S.J., Mechanic M., Mouzon E., Neve R.L., Haggarty S.J., Ren Y., Sampath S.C., Hurd Y.L., Greengard P., Tarakhovsky A., Schaefer A., Nestler E.J. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science 2010, 327:213-216.
66. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. The fifth edition of the addiction severity index. J. Subst. Abuse Treat. 1992, 9:199-213.
67. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J. Nerv. Ment. Dis. 1980, 168:26-33.
68. Mercer T.R., Dinger M.E., Mattick J.S. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 2009, 10:155-159.
69. Meyer-Lindenberg A., Kolachana B., Gold B., Olsh A., Nicodemus K.K., Mattay V., Dean M., Weinberger D.R. Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans. Mol. Psychiatry 2009, 14:968-975.
70. Michelotti G.A., Brinkley D.M., Morris D.P., Smith M.P., Louie R.J., Schwinn D.A. Epigenetic regulation of human alpha1d-adrenergic receptor gene expression: a role for DNA methylation in Sp1-dependent regulation. FASEB J. 2007, 21:1979-1993.
71. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389.
72. Nielsen D.A., Barral S., Proudnikov D., Kellogg S., Ho A., Ott J., Kreek M.J. TPH2 and TPH1: association of variants and interactions with heroin addiction. Behav. Genet. 2008, 38:133-150.
73. Nielsen D.A., Ji F., Yuferov V., Ho A., Chen A., Levran O., Ott J., Kreek M.J. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol. Psychiatry 2008, 13:417-428.
74. Nielsen D.A., Yuferov V., Hamon S., Jackson C., Ho A., Ott J., Kreek M.J. Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. Neuropsychopharmacology 2009, 34:867-873.
75. Nielsen D.A., Ho A., Bahl A., Varma P., Kellogg S., Borg L., Kreek M.J. Former heroin addicts with or without a history of cocaine dependence are more impulsive than controls. Drug Alcohol Depend. 2012, 10.1016/j.drugalcdep.2011.12.022.
76. Oertel B.G., Kettner M., Scholich K., Renne C., Roskam B., Geisslinger G., Schmidt P.H., Lötsch J. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J. Biol. Chem. 2009, 284:6530-6535.
77. Oosterhuis B.E., LaForge K.S., Proudnikov D., Ho A., Nielsen D.A., Gianotti R., Barral S., Gordon D., Leal S.M., Ott J., Kreek M.J. Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147B:793-798.
78. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., O'Brien C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28:1546-1552.
79. Pawitan Y., Seng K.C., Magnusson P.K. How many genetic variants remain to be discovered?. PLoS ONE 2009, 4:e7969.
80. Pipes G.C.T., Creemers E.E., Olson E.N. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 2006, 20:1545-1556.
81. Preker P., Nielsen J., Kammler S., Lykke-Andersen S., Christensen M.S., Mapendano C.K., Schierup M.H., Jensen T.H. RNA exosome depletion reveals transcription upstream of active human promoters. Science 2008, 322:1851-1854.
82. Pritchard J.K., Stephens M., Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000, 155:945-959.
83. Proudnikov D., Hamon S., Ott J., Kreek M.J. Association of polymorphisms in the melanocortin receptor type 2 (MC2R, ACTH receptor) gene with heroin addiction. Neurosci. Lett. 2008, 435:234-239.
84. Proudnikov D., LaForge K.S., Hofflich H., Levenstien M., Gordon D., Barral S., Ott J., Kreek M.J. Association analysis of polymorphisms in serotonin 1B receptor (HTR1B) gene with heroin addiction: a comparison of molecular and statistically estimated haplotypes. Pharmacogenet. Genomics 2006, 16:25-36.
85. Psychiatric GWAS Consortium Coordinating Committee, Cichon S., Craddock N., Daly M., Faraone S.V., Gejman P.V., Kelsoe J., Lehner T., Levinson D.F., Moran A., Sklar P., Sullivan P.F. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am. J. Psychiatry 2009, 166:540-556.
86. Renthal W., Maze I., Krishnan V., Covington H.E., Xiao G., Kumar A., Russo S.J., Graham A., Tsankova N., Kippin T.E., Kerstetter K.A., Neve R.L., Haggarty S.J., McKinsey T.A., Bassel-Duby R., Olson E.N., Nestler E.J. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007, 56:517-529.
87. Robertson K.D., Wolffe A.P. DNA methylation in health and disease. Nat. Rev. Genet. 2000, 1:11-19.
88. Seila A.C., Calabrese J.M., Levine S.S., Yeo G.W., Rahl P.B., Flynn R.A., Young R.A., Sharp P.A. Divergent transcription from active promoters. Science 2008, 322:1849-1851.
89. Saccone S.F., Bierut L.J., Chesler E.J., Kalivas P.W., Lerman C., Saccone N.L., Uhl G.R., Li C.Y., Philip V.M., Edenberg H.J., Sherry S.T., Feolo M., Moyzis R.K., Rutter J.L. Supplementing high-density SNP microarrays for additional coverage of disease-related genes: addiction as a paradigm. PLoS ONE 2009, 4:e5225.
90. Shinawi M., Schaaf C.P., Bhatt S.S., Xia Z., Patel A., Cheung S.W., Lanpher B., Nagl S., Herding H.S., Nevinny-Stickel C., Immken L.L., Patel G.S., German J.R., Beaudet A.L., Stankiewicz P. A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes. Nat. Genet. 2009, 41:1269-1271.
91. Stefansson H., Rujescu D., Cichon S., Pietilainen O.P., Ingason A., Steinberg S., Fossdal R., Sigurdsson E., Sigmundsson T., Buizer-Voskamp J.E., Hansen T., Jakobsen K.D., Muglia P., Francks C., Matthews P.M., Gylfason A., Halldorsson B.V., Gudbjartsson D., Thorgeirsson T.E., Sigurdsson A., Jonasdottir A., Bjornsson A., Mattiasdottir S., Blondal T., Haraldsson M., Magnusdottir B.B., Giegling I., Möller H.J., Hartmann A., Shianna K.V., Ge D., Need A.C., Crombie C., Fraser G., Walker N., Lonnqvist J., Suvisaari J., Tuulio-Henriksson A., Paunio T., Toulopoulou T., Bramon E., Di Forti M., Murray R., Ruggeri M., Vassos E., Tosato S., Walshe M., Li T., Vasilescu C., Mühleisen T.W., Wang A.G., Ullum H., Djurovic S., Melle I., Olesen J., Kiemeney L.A., Franke B., Sabatti C., Freimer N.B., Gulcher J.R., Thorsteinsdottir U., Kong A., Andreassen O.A., Ophoff R.A., Georgi A., Rietschel M., Werge T., Petursson H., Goldstein D.B., Nöthen M.M., Peltonen L., Collier D.A., St. Clair D., Stefansson K. Large recurrent microdeletions associated with schizophrenia. Nature 2008, 455:232-236.
92. Szilagyi A., Boór K., Székely A., Gaszner P., Kalász H., Sasvári-Székely M., Barta C. Combined effect of promoter polymorphisms in the dopamine D4 receptor and the serotonin transporter genes in heroin dependence. Neuropsychopharmacol. Hung. 2005, 7:28-33.
93. Tang J., Chen X., Xu X., Wu R., Zhao J., Hu Z., Xia K. Significant linkage and association between a functional (GT)n polymorphism in promoter of the N-methyl-d-aspartate receptor subunit gene (GRIN2A) and schizophrenia. Neurosci. Lett. 2006, 409:80-82.
94. Thoeringer C.K., Binder E.B., Salyakina D., Erhardt A., Ising M., Unschuld P.G., Kern N., Lucae S., Brueckl T.M., Mueller M.B., Fuchs B., Puetz B., Lieb R., Uhr M., Holsboer F., Mueller-Myhsok B., Keck M.E. Association of a Met88Val diazepam binding inhibitor (DBI) gene polymorphism and anxiety disorders with panic attacks. J. Psychiatr. Res. 2007, 41:579-584.
95. Thorleifsson G., Magnusson K.P., Sulem P., Walters G.B., Gudbjartsson D.F., Stefansson H., Jonsson T., Jonasdottir A., Stefansdottir G., Masson G., Hardarson G.A., Petursson H., Arnarsson A., Motallebipour M., Wallerman O., Wadelius C., Gulcher J.R., Thorsteinsdottir U., Kong A., Jonasson F., Stefansson K. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007, 317:1397-1400.
96. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., Manolescu A., Thorleifsson G., Stefansson H., Ingason A., Stacey S.N., Bergthorsson J.T., Thorlacius S., Gudmundsson J., Jonsson T., Jakobsdottir M., Saemundsdottir J., Olafsdottir O., Gudmundsson L.J., Bjornsdottir G., Kristiansson K., Skuladottir H., Isaksson H.J., Gudbjartsson T., Jones G.T., Mueller T., Gottsäter A., Flex A., Aben K.K., de Vegt F., Mulders P.F., Isla D., Vidal M.J., Asin L., Saez B., Murillo L., Blondal T., Kolbeinsson H., Stafansson J.G., Hansdottir I., Runarsdottir V., Pola R., Lindblad B., van Rij A.M., Dieplinger B., Haltmayer M., Mayordomo J.I., Kiemeney L.A., Matthiasson S.E., Oskarsson H., Tyrfingsson T., Gudbjartsson D.F., Gulcher J.R., Jonsson S., Thorsteinsdottir U., Kong A., Stefansson K. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452:638-642.
97. Tsuang M.T., Lyons M.J., Eisen S.A., Goldberg J., True W., Lin N., Meyer J.M., Toomey T., Faraone S.V., Eaves L. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am. J. Med. Genet. 1996, 67:473-477.
98. Tsuang M.T., Lyons M.J., Meyer J.M., Doyle T., Eisen S.A., Goldberg J., True W., Lin N., Toomey R., Eaves L. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch. Gen. Psychiatry 1998, 55:967-972.
99. Turic D., Langley K., Mills S., Stephens M., Lawson D., Govan C., Williams N., Van Den Bree M., Craddock N., Kent L., Owen M., O'Donovan M., Thapar A. Follow-up of genetic linkage findings on chromosome 16p13: evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol. Psychiatry 2004, 9:169-173.
100. Waga C., Ikeda K., Iwahashi K. The relationship between alcoholism and DBI gene polymorphism in Japanese--genotyping of the +529A/T in DBI gene polymorphism based on PCR. Nihon Arukoru Yakubutsu Igakkai Zasshi 2007, 42:629-634.
101. Wang J.C., Hinrichs A.L., Stock H., Budde J., Allen R., Bertelsen S., Kwon J.M., Wu W., Dick D.M., Rice J., Jones K., Nurnberger J.I., Tischfield J., Porjesz B., Edenberg H.J., Hesselbrock V., Crowe R., Schuckit M., Begleiter H., Reich T., Goate A.M., Bierut L.J. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum. Mol. Genet. 2004, 13:1903-1911.
102. Wassink T.H., Piven J., Vieland V.J., Pietila J., Goedken R.J., Folstein S.E., Sheffield V.C. Examination of AVPR1a as an autism susceptibility gene. Mol. Psychiatry 2004, 9:968-972.
103. Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
104. Xu K., Lichtermann D., Lipsky R.H., Franke P., Liu X., Hu Y., Cao L., Schwab S.G., Wildenauer D.B., Bau C.H., Ferro E., Astor W., Finch T., Terry J., Taubman J., Maier W., Goldman D. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch. Gen. Psychiatry 2004, 61:597-606.
105. Xuei X., Flury-Wetherill L., Bierut L., Dick D., Nurnberger J., Foroud T., Edenberg H.J. The opioid system in alcohol and drug dependence: family-based association study. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144:877-884.
106. Yu Y., Kranzler H.R., Panhuysen C., Weiss R.D., Poling J., Farrer L.A., Gelernter J. Substance dependence low-density whole genome association study in two distinct American populations. Hum. Genet. 2008, 123:495-506.
107. Yuferov V., Fussell D., LaForge K.S., Nielsen D.A., Gordon D., Ho A., Leal S.M., Ott J., Kreek M.J. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 2004, 14:793-804.
108. Zhang D., Shao C., Shao M., Yan P., Wang Y., Liu Y., Liu W., Lin T., Xie Y., Zhao Y., Lu D., Li Y., Jin L. Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol. Psychiatry 2007, 61:1244-1251.
109. Zhang F., Gu W., Hurles M.E., Lupski J.R. Copy number variation in human health, disease, and evolution. Annu. Rev. Genomics Hum. Genet. 2009, 10:451-481.
110. Zhang H., Kranzler H.R., Yang B.Z., Luo X., Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol. Psychiatry 2008, 13:531-543.
111. Zhang H., Luo X., Kranzler H.R., Lappalainen J., Yang B.Z., Krupitsky E., Zvartau E., Gelernter J. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum. Mol. Genet. 2006, 15:807-819.
112. Zhang Y., Wang D., Johnson A.D., Papp A.C., Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 2005, 280:32618-32624.
113. Zou Y., Liao G., Liu Y., Wang Y., Yang Z., Lin Y., Shen Y., Li S., Xiao J., Guo H., Wan C., Wang Z. Association of the 54-nucleotide repeat polymorphism of hPer3 with heroin dependence in Han Chinese population. Genes Brain Behav. 2008, 7:26-30.